Metronomic	0	10	O
5	11	12	B-Drug_or_compound
-	12	13	I-Drug_or_compound
fluorouracil	13	25	I-Drug_or_compound
,	25	26	O
oxaliplatin	27	38	B-Drug_or_compound
and	39	42	O
irinotecan	43	53	B-Drug_or_compound
in	54	56	O
colorectal	57	67	B-Pathological_formation
cancer	68	74	I-Pathological_formation
.	74	75	O

Metronomic	77	87	O
chemotherapy	88	100	O
(	101	102	O
the	102	105	O
frequent	106	114	O
,	114	115	O
long	116	120	O
term	121	125	O
,	125	126	O
low	127	130	O
dose	131	135	O
administration	136	150	O
of	151	153	O
chemotherapeutic	154	170	O
drugs	171	176	O
)	176	177	O
is	178	180	O
a	181	182	O
promising	183	192	O
therapy	193	200	O
because	201	208	O
it	209	211	O
enhances	212	220	O
the	221	224	O
anti	225	229	O
-	229	230	O
endothelial	230	241	B-Tissue
activity	242	250	O
of	251	253	O
conventional	254	266	O
chemotherapeutics	267	284	O
,	284	285	O
but	286	289	O
with	290	294	O
lower	295	300	O
or	301	303	O
no	304	306	O
toxic	307	312	O
effects	313	320	O
compared	321	329	O
to	330	332	O
maximum	333	340	O
tolerated	341	350	O
dose	351	355	O
administration	356	370	O
.	370	371	O

The	372	375	O
aims	376	380	O
of	381	383	O
the	384	387	O
present	388	395	O
study	396	401	O
were	402	406	O
to	407	409	O
compare	410	417	O
,	417	418	O
in	419	421	O
vitro	422	427	O
and	428	431	O
in	432	434	O
vivo	435	439	O
,	439	440	O
the	441	444	O
antiangiogenic	445	459	O
and	460	463	O
antitumor	464	473	B-Pathological_formation
activities	474	484	O
of	485	487	O
metronomic	488	498	O
irinotecan	499	509	B-Drug_or_compound
(	510	511	O
CPT	511	514	B-Drug_or_compound
-	514	515	I-Drug_or_compound
11	515	517	I-Drug_or_compound
)	517	518	O
,	518	519	O
oxaliplatin	520	531	B-Drug_or_compound
(	532	533	O
L	533	534	B-Drug_or_compound
-	534	535	I-Drug_or_compound
OHP	535	538	I-Drug_or_compound
)	538	539	O
and	540	543	O
5	544	545	B-Drug_or_compound
-	545	546	I-Drug_or_compound
fluorouracil	546	558	I-Drug_or_compound
(	559	560	O
5	560	561	B-Drug_or_compound
-	561	562	I-Drug_or_compound
FU	562	564	I-Drug_or_compound
)	564	565	O
in	566	568	O
colorectal	569	579	B-Pathological_formation
cancer	580	586	I-Pathological_formation
and	587	590	O
to	591	593	O
investigate	594	605	O
the	606	609	O
metronomic	610	620	O
combination	621	632	O
of	633	635	O
these	636	641	O
drugs	642	647	O
.	647	648	O

In	649	651	O
vitro	652	657	O
cell	658	662	B-Cell
proliferation	663	676	O
,	676	677	O
combination	678	689	O
studies	690	697	O
and	698	701	O
vascular	702	710	B-Gene_or_gene_product
endothelial	711	722	I-Gene_or_gene_product
growth	723	729	I-Gene_or_gene_product
factor	730	736	I-Gene_or_gene_product
(	737	738	O
VEGF	738	742	B-Gene_or_gene_product
)	742	743	O
secretion	744	753	O
analyses	754	762	O
were	763	767	O
performed	768	777	O
on	778	780	O
endothelial	781	792	B-Cell
(	793	794	I-Cell
HMVEC	794	799	I-Cell
-	799	800	I-Cell
d	800	801	I-Cell
)	801	802	I-Cell
and	803	806	O
colorectal	807	817	B-Cell
cancer	818	824	I-Cell
(	825	826	I-Cell
HT	826	828	I-Cell
-	828	829	I-Cell
29	829	831	I-Cell
)	831	832	I-Cell
cells	833	838	I-Cell
exposed	839	846	O
for	847	850	O
144	851	854	O
h	855	856	O
to	857	859	O
metronomic	860	870	O
concentrations	871	885	O
of	886	888	O
SN	889	891	B-Drug_or_compound
-	891	892	I-Drug_or_compound
38	892	894	I-Drug_or_compound
,	894	895	O
the	896	899	O
active	900	906	O
metabolite	907	917	O
of	918	920	O
CPT	921	924	B-Drug_or_compound
-	924	925	I-Drug_or_compound
11	925	927	I-Drug_or_compound
,	927	928	O
L	929	930	B-Drug_or_compound
-	930	931	I-Drug_or_compound
OHP	931	934	I-Drug_or_compound
and	935	938	O
5	939	940	B-Drug_or_compound
-	940	941	I-Drug_or_compound
FU	941	943	I-Drug_or_compound
.	943	944	O

HT	945	947	B-Cell
-	947	948	I-Cell
29	948	950	I-Cell
human	951	956	B-Organism
colorectal	957	967	B-Pathological_formation
cancer	968	974	I-Pathological_formation
xenograft	975	984	I-Pathological_formation
model	985	990	I-Pathological_formation
was	991	994	O
used	995	999	O
and	1000	1003	O
tumour	1004	1010	B-Pathological_formation
growth	1011	1017	O
,	1017	1018	O
microvessel	1019	1030	B-Tissue
density	1031	1038	O
and	1039	1042	O
VEGF	1043	1047	B-Gene_or_gene_product
quantification	1048	1062	O
were	1063	1067	O
performed	1068	1077	O
in	1078	1080	O
tumours	1081	1088	B-Pathological_formation
after	1089	1094	O
the	1095	1098	O
administration	1099	1113	O
of	1114	1116	O
metronomic	1117	1127	O
CPT	1128	1131	B-Drug_or_compound
-	1131	1132	I-Drug_or_compound
11	1132	1134	I-Drug_or_compound
,	1134	1135	O
L	1136	1137	B-Drug_or_compound
-	1137	1138	I-Drug_or_compound
OHP	1138	1141	I-Drug_or_compound
,	1141	1142	O
5	1143	1144	B-Drug_or_compound
-	1144	1145	I-Drug_or_compound
FU	1145	1147	I-Drug_or_compound
and	1148	1151	O
their	1152	1157	O
simultaneous	1158	1170	O
combination	1171	1182	O
.	1182	1183	O

Low	1184	1187	O
concentrations	1188	1202	O
of	1203	1205	O
SN	1206	1208	B-Drug_or_compound
-	1208	1209	I-Drug_or_compound
38	1209	1211	I-Drug_or_compound
,	1211	1212	O
but	1213	1216	O
not	1217	1220	O
5	1221	1222	B-Drug_or_compound
-	1222	1223	I-Drug_or_compound
FU	1223	1225	I-Drug_or_compound
and	1226	1229	O
L	1230	1231	B-Drug_or_compound
-	1231	1232	I-Drug_or_compound
OHP	1232	1235	I-Drug_or_compound
,	1235	1236	O
preferentially	1237	1251	O
inhibited	1252	1261	O
endothelial	1262	1273	B-Cell
cell	1274	1278	I-Cell
proliferation	1279	1292	O
.	1292	1293	O

Simultaneous	1294	1306	O
and	1307	1310	O
continuous	1311	1321	O
exposure	1322	1330	O
of	1331	1333	O
HT	1334	1336	B-Cell
-	1336	1337	I-Cell
29	1337	1339	I-Cell
and	1340	1343	O
HMVEC	1344	1349	B-Cell
-	1349	1350	I-Cell
d	1350	1351	I-Cell
cells	1352	1357	I-Cell
to	1358	1360	O
low	1361	1364	O
concentrations	1365	1379	O
SN	1380	1382	B-Drug_or_compound
-	1382	1383	I-Drug_or_compound
38	1383	1385	I-Drug_or_compound
+	1385	1386	O
L	1386	1387	B-Drug_or_compound
-	1387	1388	I-Drug_or_compound
OHP	1388	1391	I-Drug_or_compound
+	1391	1392	O
5	1392	1393	B-Drug_or_compound
-	1393	1394	I-Drug_or_compound
FU	1394	1396	I-Drug_or_compound
for	1397	1400	O
144	1401	1404	O
h	1405	1406	O
showed	1407	1413	O
a	1414	1415	O
strong	1416	1422	O
antagonism	1423	1433	O
and	1434	1437	O
an	1438	1440	O
unfavorable	1441	1452	O
dose	1453	1457	O
-	1457	1458	O
reduction	1458	1467	O
index	1468	1473	O
.	1473	1474	O

Moreover	1475	1483	O
,	1483	1484	O
the	1485	1488	O
ternary	1489	1496	O
combination	1497	1508	O
resulted	1509	1517	O
in	1518	1520	O
a	1521	1522	O
significant	1523	1534	O
increase	1535	1543	O
of	1544	1546	O
VEGF	1547	1551	B-Gene_or_gene_product
secretion	1552	1561	O
in	1562	1564	O
HT	1565	1567	B-Cell
-	1567	1568	I-Cell
29	1568	1570	I-Cell
cancer	1571	1577	I-Cell
cells	1578	1583	I-Cell
.	1583	1584	O

In	1585	1587	O
a	1588	1589	O
xenograft	1590	1599	O
model	1600	1605	O
metronomic	1606	1616	O
CPT	1617	1620	B-Drug_or_compound
-	1620	1621	I-Drug_or_compound
11	1621	1623	I-Drug_or_compound
,	1623	1624	O
but	1625	1628	O
not	1629	1632	O
5	1633	1634	B-Drug_or_compound
-	1634	1635	I-Drug_or_compound
FU	1635	1637	I-Drug_or_compound
and	1638	1641	O
L	1642	1643	B-Drug_or_compound
-	1643	1644	I-Drug_or_compound
OHP	1644	1647	I-Drug_or_compound
,	1647	1648	O
significantly	1649	1662	O
inhibits	1663	1671	O
HT	1672	1674	B-Pathological_formation
-	1674	1675	I-Pathological_formation
29	1675	1677	I-Pathological_formation
tumor	1678	1683	I-Pathological_formation
growth	1684	1690	O
and	1691	1694	O
microvessel	1695	1706	B-Tissue
density	1707	1714	O
in	1715	1717	O
the	1718	1721	O
absence	1722	1729	O
of	1730	1732	O
toxicity	1733	1741	O
.	1741	1742	O

On	1743	1745	O
the	1746	1749	O
contrary	1750	1758	O
,	1758	1759	O
metronomic	1760	1770	O
5	1771	1772	B-Drug_or_compound
-	1772	1773	I-Drug_or_compound
FU	1773	1775	I-Drug_or_compound
+	1775	1776	O
L	1776	1777	B-Drug_or_compound
-	1777	1778	I-Drug_or_compound
OHP	1778	1781	I-Drug_or_compound
+	1781	1782	O
CPT	1782	1785	B-Drug_or_compound
-	1785	1786	I-Drug_or_compound
11	1786	1788	I-Drug_or_compound
therapy	1789	1796	O
did	1797	1800	O
not	1801	1804	O
affect	1805	1811	O
the	1812	1815	O
microvascular	1816	1829	B-Tissue
count	1830	1835	O
.	1835	1836	O

The	1837	1840	O
metronomic	1841	1851	O
concept	1852	1859	O
might	1860	1865	O
not	1866	1869	O
universally	1870	1881	O
apply	1882	1887	O
to	1888	1890	O
every	1891	1896	O
cytotoxic	1897	1906	O
drug	1907	1911	O
in	1912	1914	O
colorectal	1915	1925	B-Pathological_formation
cancer	1926	1932	I-Pathological_formation
and	1933	1936	O
metronomic	1937	1947	O
combination	1948	1959	O
regimens	1960	1968	O
should	1969	1975	O
be	1976	1978	O
used	1979	1983	O
with	1984	1988	O
caution	1989	1996	O
.	1996	1997	O

